| Item Type | Name |
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
|
Academic Article
|
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
|
|
Academic Article
|
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
|
|
Academic Article
|
Natalizumab induction and maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
|
|
Academic Article
|
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
|
|
Academic Article
|
General principles and pharmacology of biologics in inflammatory bowel disease.
|
|
Academic Article
|
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
|
Academic Article
|
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
|
|
Academic Article
|
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
|
|
Academic Article
|
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
|
|
Academic Article
|
Maintenance therapy with certolizumab pegol for Crohn's disease.
|
|
Academic Article
|
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
|
|
Academic Article
|
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Management of inflammatory bowel disease: past, present and future.
|
|
Academic Article
|
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
|
Academic Article
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
|
Academic Article
|
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
|
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
|
Academic Article
|
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
|
|
Academic Article
|
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
|
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
|
Academic Article
|
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
|
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
|
Academic Article
|
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
|
|
Academic Article
|
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
|
|
Academic Article
|
Briakinumab for treatment of Crohn's disease: results of a randomized trial.
|
|
Academic Article
|
Checkpoint Inhibitor-Induced Colitis.
|
|
Academic Article
|
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
|
|
Academic Article
|
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
|